PD-L1 Antibody | Affinity Biosciences LTD|亲科生物官网

WB
Cites

1/10

Western blot analysis of extracts from various samples, using CD274 Antibody.

Fig.

Figure 8| qRT-PCR and western blot results.

Fig 7.

Figure2 qRT-PCR and Western blot results (a) show that CD274 and IL8 were upregulated in the basal-like breast cancer cell lines, BT549 and MDA-MB-231 (p.

Figure 3.

Fig.

FIGURE 2 Association of JAK2/STAT3 signaling pathway activation with acquired radioresistance.

Figure 1.

产品:	PD-L1 抗体
货号:	DF6526
描述:	Rabbit polyclonal antibody to PD-L1
应用:	WB
反应:	Human, Mouse, Rat
预测:	Bovine, Horse, Sheep, Rabbit, Dog
分子量:	33kDa, 40~70kD(Glycosylated); 33kD(Calculated).
蛋白号:	Q9NZQ7
RRID:	AB_2838488

浏览相似产品>>

阻断肽(封闭肽)是特异性结合目标抗体和阻断抗体结合的多肽。这些多肽包含抗体识别的抗原表位。与阻断肽结合的抗体不再与靶蛋白上的表位结合。例如，在免疫印迹(WB)和免疫组化(IHC)中，通过比较被阻断抗体和未阻断抗体的染色，可以看到哪种染色是特异性的。

规格	价格	库存
50ul	RMB¥ 1250	现货
100ul	RMB¥ 2300	现货
200ul	RMB¥ 3000	现货

货期: 当天发货

联系销售

实验方案

产品描述

来源:

Rabbit

应用:

WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:

Human,Mouse,Rat

预测:

Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(92%)

克隆:

Polyclonal

特异性:

CD274 Antibody detects endogenous levels of total CD274.

RRID:

AB_2838488
引用格式: Affinity Biosciences Cat# DF6526, RRID:AB_2838488.

偶联:

Unconjugated.

纯化:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

保存:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

别名:

展开/折叠

B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD-L1; PD1L1_HUMAN; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed cell death 1 ligand 1; Programmed death ligand 1; RGD1566211;

抗原和靶标

免疫原:

Uniprot:

Q9NZQ7(PD1L1_HUMAN) >>Visit HPA database.

基因/基因ID:

CD274(29126)

表达:

Q9NZQ7 PD1L1_HUMAN:

Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.

描述:

Programmed cell death ligand 1(CD274, or B7-H1, PD-L1), is the first member of B7 family to be discovered. B7 family molecules are type I transmembrane proteins belonging to the immunoglobulin superfamily. In concert with their CD28 family receptors, the B7s are key regulators of the adaptive immune response. CD274 is suggested a negative regulator of T and B cell, and play important role in mediating tolerance of lymphocytes to self-antigens. It also involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

序列:

Q9NZQ7 PD1L1_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET

种属预测

种属预测:

score>80的预测可信度较高，可尝试用于WB检测。*预测模型主要基于免疫原序列比对，结果仅作参考，不作为质保凭据。

Species

Results

Score

Horse

100

Bovine

100

Sheep

100

Rabbit

100

Dog

Pig

Xenopus

Zebrafish

Chicken

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - Q9NZQ7 作为底物

Q9NZQ7

Site	PTM Type	Source
N192	N-Glycosylation	Uniprot
S195	Phosphorylation	Uniprot
K270	Acetylation	Uniprot
S283	Phosphorylation	Uniprot
T290	Phosphorylation	Uniprot

研究背景

Q9NZQ7_PD1L1_HUMAN

功能:

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).

The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

翻译修饰:

Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation.

细胞定位:

Cell membrane>Single-pass type I membrane protein. Early endosome membrane>Single-pass type I membrane protein. Recycling endosome membrane>Single-pass type I membrane protein.
Note: Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation.

Cell membrane>Single-pass type I membrane protein.

Endomembrane system>Single-pass type I membrane protein.

组织特异性:

亚基结构:

Interacts with PDCD1. Interacts (via transmembrane domain) with CMTM4 and CMTM6.

蛋白家族:

Belongs to the immunoglobulin superfamily. BTN/MOG family.

研究领域

· Environmental Information Processing > Signaling molecules and interaction > Cell adhesion molecules (CAMs). (View pathway)

文献引用

1). A Hybrid Nanoadjuvant Simultaneously Depresses PD-L1/TGF-β1 and Activates cGAS-STING Pathway to Overcome Radio-Immunotherapy Resistance. Advanced materials (Deerfield Beach, Fla.), 2024 (PubMed: 38229577) [IF=29.4]

2). Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance. ACS nano, 2024 (PubMed: 38227812) [IF=17.1]

3). Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy. Acta pharmaceutica Sinica. B, 2024 (PubMed: 39309498) [IF=14.5]

Application: WB Species: Mouse Sample: 4T1 lung tumor cells

Figure 1. Effects of TPP-TAM on the expression of PD-L1 and TGF-β protein in 4T1 lung tumor cells. (A) The preparation process of TPP-TAM and its merits compared with TAM. (B) Evaluation of the effects of different concentrations of TAM or TPP-TAM on the function of mitochondrial complex Ⅰ (n = 3). (C) Detection of the changes of mitochondrial membrane potential by JC-1 fluorescence (monomer, green) after PBS, 20 μmol/L TPP-C6, 20 μmol/L TAM, 2 μmol/L TPP-TAM, or 10 μmol/L CCCP treatment, scale bar = 5 μm. (D) Detection of the ADP/ATP ratio at different time after 2 μmol/L TPP-TAM treatment (n = 3). (E–I) Evaluation and quantification of the expression levels of PD-L1, AMPK, pAMPK, and TGF-β proteins by Western blot assay (n = 3). All data are presented as mean ± SD. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.

4). LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma. International Immunopharmacology, 2020 (PubMed: 33221703) [IF=5.6]

Application: WB Species: Human Sample: hepatocellular carcinoma tissue

Fig 7. The relationship between MIAT and PD-L1 and sorafenib resistance was verified in vitro. (A) There was a positive correlation between MIAT and PD-L1 expression in HCC tissue samples. (B) The expression of MIAT was positively correlated with CTLA4 in HCC tissue samples. (C) In HCC cells, the expression of PD-L1 mRNA decreased after the knockdown of MIAT. (D) Knockdown of MIAT down regulated the expression of PD-L1 protein in HCC cells. (E) The level of MIAT increased after sorafenib treatment. (F) The level of PD-L1 increased after sorafenib treatment. (G) MIAT affects the proliferation of HCC cells. *: P < 0.05; **: P < 0.01; ***: P < 0.001; ****: P < 0.0001.

5). miR‑576‑3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD‑L1 and cyclin D1. Molecular Medicine Reports, 2021 (PubMed: 33236151) [IF=3.4]

6). Homeobox D9 drives the malignant phenotypes and enhances the Programmed death ligand-1 expression in non-small cell lung cancer cells via binding to Angiopoietin-2 promoter. World Journal of Surgical Oncology, 2023 (PubMed: 36907878) [IF=3.2]

Application: WB Species: Human Sample: NSCLC cells

Fig. 7 HOXD9 has the ability to stimulate PD-L1 expression in NSCLC cells. NCI-H661 cells were transfected with exHOXD9 or empty vector, while NCI-H292 cells were transfected with siHOXD9#1, siHOXD9#2 or their negative control siNC. A After 48 h of transfection, total PD-L1 protein expression in two NSCLC cells (NCI-H661 and NCI-H292) was evaluated by western blot assay. B After 48 h of transfection, soluble PD-L1 protein expression in two NSCLC cells was evaluated by ELISA assay. C After 48 h of transfection, membrane PD-L1 protein expression in NCI-H292 cells was evaluated by flow cytometry analysis. MFI, relative mean fluorescence intensity. ** p

7). lncRNA MIAT targets miR‐411‐5p/STAT3/PD‐L1 axis mediating hepatocellular carcinoma immune response. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2022 (PubMed: 35429078) [IF=3.0]

8). Baicalein Enhances Radiosensitivity in Colorectal Cancer via JAK2/STAT3 Pathway Inhibition. Chemical biology & drug design, 2024 (PubMed: 39152534) [IF=3.0]

Application: WB Species: Mouse Sample: CT26-R Cells

FIGURE 2 Association of JAK2/STAT3 signaling pathway activation with acquired radioresistance. Comparison of the expression levels of p-STAT3 (Tyr705), JAK2, PD-L1, and SOCS3 between parental (CT26) and acquired radioresistance (CT26-R) cells. *p

9). PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells. Immunological Investigations, 2023 (PubMed: 36762677) [IF=2.8]

10). Screening of immunosuppressive factors for biomarkers of breast cancer malignancy phenotypes and subtype-specific targeted therapy. PeerJ, 2022 (PubMed: 31293831) [IF=2.7]

Application: WB Species: human Sample: T549 and MDA-MB-231 cell； MCF7 and T47D cell

Figure 8| qRT-PCR and western blot results. (A, B) qRT-PCR results showed that CD274 and IL8 were upregulated in the basal-like breast cancer cell lines BT549 and MDA-MB-231 (p < 0.0001). Similar to the qRT-PCR results, the western blot analysis (C–E) indicated that CD274 and IL8 protein were increased in the BT549 and MDA-MB-231 cell lines compared to the MCF7 and T47D cell lines. P < 0.001, p < 0.01, and p < 0.05

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.

PD-L1 Antibody - #DF6526

产品推荐

相关下载

MS Report

HPLC Report

MSDS

说明书

COA